Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 599 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tumors Metastatic to Brain Clear all
Terminated Phase 2 Interventional

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

NCT00538343
View directory record Official record
Conditions
Brain Metastases
Interventions
berubicin hydrochloride (RTA 744)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Early Phase 1 Interventional Results available

Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes

NCT02774291
View directory record Official record
Conditions
HLA-A2 Positive Cells Present, Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Aldesleukin, Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes, Cyclophosphamide, Filgrastim, Fludarabine Phosphate, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 66 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 12, 2026, 7:03 PM EDT
Active, not recruiting Phase 3 Interventional

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

NCT03741673
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

NCT00003911
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Phase 1 Interventional

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

NCT05388877
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Melanoma
Interventions
Dabrafenib, MEK-1/MEKK-1 Inhibitor E6201, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 12, 2026, 7:03 PM EDT
Completed Not applicable Interventional

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

NCT01727531
View directory record Official record
Conditions
Brain Metastasis
Interventions
Chloroquine diphosphate
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 12, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

NCT00623766
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Corticosteroid: Betamethasone, Corticosteroid: Dexamethasone, Corticosteroid: Fludrocortisone, Corticosteroid: Hydrocortisone, Corticosteroid: Meprednisone, Corticosteroid: Methylprednisolone, Corticosteroid: Prednisolone, Corticosteroid: Prednisone, Corticosteroid: Triamcinolone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
14
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 12, 2026, 7:03 PM EDT
Recruiting Phase 1 Interventional

OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

NCT07655583
View directory record Official record
Conditions
Brain Metastasis, Stereotactic Radiosurgery, Resection, Systemic Therapy
Interventions
Systemic therapy
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Active, not recruiting Not applicable Interventional Results available

Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases

NCT03391362
View directory record Official record
Conditions
Brain Metastases, Small Cell Lung Cancer
Interventions
Stereotactic Radiation
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

NCT00362817
View directory record Official record
Conditions
Brain Tumor, Brain Metastases
Interventions
carboplatin, temozolomide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 12, 2026, 7:03 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Neurococognitive and Functioal Assessment of Patients With Brain Metastases

NCT01861405
View directory record Official record
Conditions
Cerebral Metastases Patients
Interventions
neuropsychological testing and quality of life assessments, Standard of Care WBRT or SRS, Functional magnetic resonance imaging
Behavioral · Radiation · Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 12, 2026, 7:03 PM EDT
Withdrawn Phase 4 Interventional

Genetically-informed Therapies for Patients With Metastatic Cancer

NCT02000739
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Genetically Informed Therapy
Genetic
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)

NCT02460874
View directory record Official record
Conditions
Cerebral Edema, Brain Metastases
Interventions
Glyburide, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

NCT00476827
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Docetaxel, CPT-11, Paclitaxel, Vinorelbine Tartrate, Gemcitabine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 12, 2026, 7:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
Interventions
silevertinib (BDTX-1535) monotherapy
Drug
Lead sponsor
Black Diamond Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis

NCT04516070
View directory record Official record
Conditions
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Completed Not applicable Interventional Results available

Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases

NCT02514915
View directory record Official record
Conditions
Malignant Neoplasm Brain
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
Christopher Wilke
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 12, 2026, 7:03 PM EDT
Not listed Phase 2 Interventional

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

NCT00805636
View directory record Official record
Conditions
Brain Metastases, Solid Tumors
Interventions
2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10), Stereotactic Radio-Surgery (SRS) therapy, Positron Emission Tomography
Drug · Radiation · Procedure
Lead sponsor
Aposense Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Oct 12, 2026, 7:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

NCT03449238
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Pembrolizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Recruiting Phase 2Phase 3 Interventional

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
RO7771950, Tucatinib, Trastuzumab, Capecitabine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
14
States / cities
Huntsville, Alabama • Gilbert, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Recruiting Not applicable Interventional

Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

NCT02754544
View directory record Official record
Conditions
Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
Interventions
Direct Electrocortical Stimulation, Electrocorticography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate

NCT02581839
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Eribulin Mesylate, MRI, Pre-Medication: Zofran, Pre-Medication: Decadron
Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 12, 2026, 7:03 PM EDT
Recruiting Phase 2 Interventional

NTS-WBRT in Brain Metastases

NCT05013892
View directory record Official record
Conditions
Brain Metastases
Interventions
NTS-WBRT (normal tissue sparing whole brain radiation therapy), Memantine
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 12, 2026, 7:03 PM EDT
Terminated Not applicable Interventional

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

NCT03717142
View directory record Official record
Conditions
Low Grade Glioma of Brain, Glioblastoma, Metastasis to Brain
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 12, 2026, 7:03 PM EDT